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ABSTRACT
Purpose: Patients with chronic spontaneous urticaria (CSU) have an increased risk for 
comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we 
evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid 
autoimmune diseases.
Methods: We analyzed records of CSU patients (n = 1,199) for a history or presence of 
autoimmune diseases. Patients were diagnosed with type IIb autoimmune CSU (aiCSU) if all 
3 tests were positive: autologous serum skin test (ASST), basophil histamine release assay 
(BHRA) and/or basophil activation test (BAT), and IgG autoantibodies against FcεRIα/IgE 
detected by immunoassay.
Results: Twenty-eight percent of CSU patients had at least 1 autoimmune disease. The most 
prevalent autoimmune diseases were Hashimoto's thyroiditis (HT) (≥ 21%) and vitiligo 
(2%). Two percent of CSU patients had ≥ 2 autoimmune diseases, most frequently HT 
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plus vitiligo. Comorbid autoimmune diseases, in patients with CSU, were associated with 
female sex, a family history of autoimmune diseases, and higher rates of hypothyroidism 
and hyperthyroidism (P < 0.001). Presence of autoimmune diseases was linked to aiCSU 
(P = 0.02). The risks of having autoimmune diseases were 1.7, 2.9 and 3.3 times higher for 
CSU patients with a positive ASST, BHRA and BAT, respectively. In CSU patients, markers 
for autoimmune diseases, antinuclear antibodies and/or IgG anti-thyroid antibodies were 
associated with non-response to omalizumab treatment (P = 0.013).
Conclusions: In CSU, autoimmune diseases are common and linked to type IIb autoimmune 
CSU. Our results suggest that physicians assess and monitor all adult patients with CSU for 
signs and symptoms of common autoimmune diseases, especially HT and vitiligo.
Keywords: Chronic urticaria; autoimmune diseases; autoimmune thyroiditis; autoantibodies; 
autoimmunity; omalizumab; vitiligo; immunoassay
INTRODUCTION
Chronic spontaneous urticaria (CSU) is defined as the spontaneous occurrence of 
wheals, angioedema or both for > 6 weeks due to known or unknown causes.1 While exact 
pathomechanisms underlying CSU are, as of yet, not completely unraveled, there is strong 
evidence to support a link to autoimmunity.2,3
Recently, 2 endotypes of CSU have been proposed: type I autoimmune CSU mediated by IgE 
autoantibodies (also known as autoallergic CSU) and type IIb autoimmune CSU (aiCSU),4-7 
in which IgG autoantibodies, and probably IgM and IgA are responsible for direct activation 
of mast cells by binding to high-affinity IgE receptors.3,8 Positive autologous serum skin 
test (ASST), basophil histamine release assay (BHRA) and immunoassay for specific IgG 
autoantibodies against FcεRIα/IgE are the current gold standard for the diagnosis of aiCSU.9 
At least 8% of CSU patients have aiCSU and they are more severely affected with markedly 
lower total IgE levels,4 and higher rates of eosinopenia and basopenia.10
On the other hand, CSU patients are known to often exhibit comorbid autoimmune 
disorders,4,11-14 mostly Hashimoto's thyroiditis (HT), vitiligo and rheumatoid arthritis.11,12 
Also, CSU has been described to occur in patients with common autoimmune diseases 
such as autoimmune thyroid disease (AITD) and relatively rare autoimmune disorders, e.g. 
autoimmune encephalitis.11,15-17 CSU is thought to occur more frequently in patients with 
AITD, systemic lupus erythematosus (SLE), rheumatoid arthritis or celiac disease.11,17
Three reasons underline the importance of research on the role and relevance of autoimmune 
diseases in CSU. First, the presence of autoimmune diseases in patients with CSU may 
predict the duration, activity and course of CSU and the response to treatment. Secondly, 
various features of CSU may be associated with a higher risk of having comorbid autoimmune 
diseases. Knowledge of these features can help facilitate early diagnosis of comorbid 
autoimmune diseases in patients with CSU. Thirdly, therapeutic interventions in patients 
with CSU and concomitant autoimmune diseases need to be aligned to assure maximum 
efficacy as well as minimum drug interactions and adverse effects. For example, CSU 
treatment, e.g. omalizumab or cyclosporine, may also be effective in some other autoimmune 
diseases, e.g. SLE,18 bullous pemphigoid,19 eosinophilic granulomatosis with polyangiitis20 
and autoimmune polyglandular syndromes.21
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Thus, the link between CSU and autoimmunity has been known for many years, although the 
specific distribution of autoimmune diseases in different CSU phenotypes and endotypes 
is less characterized. In this multicenter retrospective study with more than 1,000 CSU 
patients, we evaluated clinical and laboratory factors associated with a higher risk of having 
autoimmune diseases and we characterized this subpopulation of patients.
MATERIALS AND METHODS
Patients
We analyzed data from 1,199 CSU patients from the urticaria specialty clinics of Charite-
Universitätsmedizin Berlin, Germany (n = 791), I.M. Sechenov First Moscow State Medical 
University, Russia (n = 249) and 10 further collaborating urticaria centers (n = 159, the 
PURIST study, some data have been published before4). Patient data were analyzed 
retrospectively. The study followed Good Clinical Practice guidelines and the Declaration 
of Helsinki, ethics approval was obtained by each of the cooperating centers as required, 
and all patients provided signed informed consent. CSU was defined as recurrent whealing, 
angioedema, or both for > 6 weeks due to known or unknown causes and without definite 
triggers. Patients with chronic inducible urticaria alone and patients with urticarial vasculitis 
were excluded.
Autoimmune diseases
We analyzed the patients' records for a history or presence of autoimmune diseases 
including vitiligo, rheumatoid arthritis, celiac disease, type I diabetes mellitus, SLE, 
autoimmune gastritis/pernicious anemia, ankylosing spondylitis, alopecia areata, myasthenia 
gravis, antiphospholipid syndrome, scleroderma, idiopathic thrombocytopenic purpura, 
dermatomyositis, primary biliary cirrhosis and autoimmune hepatitis. CSU patients with 
several other conditions such as psoriasis, endometriosis, fibromyalgia, sensorineural 
hearing loss and thrombocytopenia, in which an autoimmune nature of the disease has 
been discussed, but not ultimately confirmed, were excluded from the analyses unless other 
autoimmune diseases were present. AITD was assessed if diagnosed by a physician and/or 
elevated levels of IgG anti-TPO with euthyroidism, hypothyroidism (HT) or hyperthyroidism 
(Graves' disease) were present. A few patients with CSU and hypothyroidism might have 
normal thyroid hormones levels because of the levothyroxine treatment.
Clinical and laboratory parameters
Blood was drawn and analyzed for routine patient care. From the patients' record, we 
extracted data on age, sex, duration of CSU, presence of concomitant angioedema, family 
history of autoimmune diseases, disease activity and ASST results, complete blood count, 
antinuclear antibodies (ANA), serum total IgE and IgG anti-TPO levels, when available.
We analyzed rates of autoimmune diseases in 4 age groups of CSU patients (< 20, 20–29, 
30–39, > 39 years) based on the previously reported data on the most common mean age-of-
onset of autoimmune diseases of 20–29 and 40–50 years.22 Disease activity was determined 
using the urticaria activity score (UAS), which was calculated as the sum of the itch (no = 0, 
mild = 1, moderate = 2, intense = 3) and the wheal score (no wheals = 0, < 20 wheals/24 hr = 
1, 20–50 wheals/24 hr = 2, > 50 wheals/24 hr = 3) for 7 consecutive days (UAS7, minimum = 
0, maximum = 42). CSU patients were divided into 3 groups according to CSU activity: low 
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disease activity = 0–15 (urticaria-free, well-controlled CSU or mild CSU); moderate disease 
activity = 16–27 (moderate CSU); and high disease activity = 28–42 (severe CSU).23
Type IIb autoimmune CSU
The aiCSU is defined according to an agreed set of 3 diagnostic criteria: (a) positive in vivo 
autoreactivity (positive ASST); (b) positive in vitro BHRA and/or basophil activation test (BAT) 
as evidence of functional serum histamine-releasing autoantibodies in patients' sera that are 
directed against IgE or high-affinity IgE receptors; and (c) a positive immunoassay for detection 
of IgG autoantibodies against FcεRIα and/or anti-IgE. The ASST is a screening test for aiCSU 
that evaluates the presence of histamine-releasing serum factors of any type, including IgG 
autoantibodies against FcεRIα or IgE. The ASST is regarded as positive when the serum wheal is 
≥ 1.5 mm as compared to the negative control (saline).24 In CSU patients from the PURIST study 
(n = 159), all three aiCSU-defining tests were performed as previously described.4
Most analyses were performed in all centers, except BHRA/BAT, IgG anti-FcεRIα/IgE (data 
from the PURIST study) and UAS7 (data from the urticaria clinic of Berlin and the PURIST 
study). UAS7 was usually calculated seven days before the blood sampling and ASST.
Response to treatment
The association between the presence of markers of autoimmune diseases, namely ANA 
and IgG anti-TPO, and omalizumab 300 mg treatment was retrospectively analyzed in 45 
CSU patients from the Berlin cohort. Of 45 patients, seven, 18, and 20 were non-responders 
(a reduction in UAS7 of less than 30%), partial responders (a reduction in UAS7 of 30% 
to 89%) and complete responders (a reduction of 90% or more from baseline in UAS7) to 
omalizumab, respectively. Pre-omalizumab treatment measurements of ANA and IgG anti-
TPO were used for this analysis.
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Science (IBM 
SPSS version 25.0; IBM Corp, New York, NY, USA). Figures were made using GraphPad Prism 
6 (GraphPad Software, La Jolla, CA, USA). Due to the methodology, there were missing 
data for some variables, and some analyses were performed in subgroups. Demographic 
characteristics of CSU patients were reported using descriptive statistics. Because data were 
not distributed normally, non-parametric tests were used. Groups were compared using 
the Mann-Whitney U test, the chi-square test of homogeneity and Fisher's exact test (if data 
violated the sample size adequacy assumption). P values < 0.05 were considered significant. 
Post hoc analysis involved pairwise comparisons using the z test of 2 proportions or multiple 
Fisher's exact tests with Bonferroni correction (statistical significance was set at P < 0.02).
RESULTS
Autoimmune diseases, mostly HT, are common in CSU patients
Of 1,199 CSU patients, 28% (n = 333) had one or more comorbid autoimmune disease (Table 1).  
The most prevalent disease was AITD (25%, mostly HT, ≥ 21%). Other autoimmune 
comorbidities were seen in 3% of cases, mainly vitiligo (2%) and rheumatoid arthritis (1%). 
Of the 333 CSU patients with a comorbid autoimmune disease, 91% had one, most often 
AITD, 8% had 2, and less than 1% had 3 (Table 2). About 1% of all CSU patients had HT and 
vitiligo, the most frequent combination of 2 comorbid autoimmune diseases (Table 2).
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CSU patients who were 40 years or older had autoimmune comorbidities, especially AITD, 
RA and vitiligo, more often than younger patients (Table 1).
Autoimmune comorbidities, in patients with CSU, are associated with being 
female and having a family history of autoimmunity
Autoimmune comorbidities were reported more frequently in female CSU patients (risk ratio 
[RR] = 2.3, P < 0.001) and patients with a family history of autoimmune diseases (RR = 2.0, P 
< 0.001; Table 3, Supplementary Table S1). Patients with angioedema also had higher rates of 
comorbid autoimmune diseases (RR = 1.2, P = 0.05, Table 3).
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Table 1. The prevalence of autoimmune diseases in CSU patients
Disease Prevalence of AID 
in the general 
population,%*
Prevalence of AID in CSU
% (No./total) Years of age, % of total Sex, %
< 20 20–29 30–39 > 39 F M
Any AID 3.9–10.6 27.8 (333/1,199)† 0.5 4.7 4.9 17.5 32.7 14.2
Autoimmune thyroid disease 2.6–4.8 25.4 (305/1,199)‡ 0.5 4.2 4.6 15.9 31.2 11.7
Vitiligo 0.02–0.2 2.3 (20/885) 0.1 0.5 0.3 1.2 1.8 3.2
Rheumatoid arthritis 0.1–0.5 1.0 (9/874) 0.0 0.0 0.1 0.9 1.0 1.1
Autoimmune gastritis 0.03–0.1 0.9 (7/755)§ 0.0 0.0 0.4 0.5 1.2 0.4
Diabetes mellitus type I 0.1–0.6 0.5 (4/752) 0.0 0.1 0.3 0.1 0.4 0.8
Ankylosing spondylitis 0.07–0.1 0.5 (4/869) 0.0 0.0 0.0 0.5 0.5 0.4
Celiac disease 0.2–0.3 0.3 (2/750) 0.0 0.3 0.0 0.0 0.4 0.0
Primary biliary cirrhosis 0.01–0.03 0.2 (2/867) 0.0 0.0 0.1 0.1 0.3 0.0
Autoimmune hepatitis 0.01–0.02 0.2 (2/920) 0.0 0.1 0.1 0.0 0.4 0.0
Alopecia areata 0.2 0.1 (1/866) 0.0 0.1 0.0 0.0 0.0 0.4
Myasthenia gravis 0.008–0.04 0.1 (1/920) 0.0 0.0 0.0 0.1 0.0 0.5
Antiphospholipid syndrome 0.03–0.04 0.1 (1/749) 0.0 0.1 0.0 0.0 0.2 0.0
Scleroderma 0.009–0.08 0.1 (1/749) 0.0 0.0 0.0 0.1 0.2 0.0
ITP 0.04–0.06 0.1 (1/920) 0.0 0.0 0.0 0.1 0.2 0.0
SLE 0.03–0.15 0.1 (1/866) 0.0 0.0 0.1 0.0 0.2 0.0
Dermatomyositis 0.008–0.019 0 (0/865) 0.0 0.0 0.0 0.0 0.0 0.0
CSU, chronic spontaneous urticaria; AID, autoimmune diseases; F: female; M: male; ITP, idiopathic thrombocytopenic purpura; SLE, systemic lupus erythematosus.
*References25,53; †Some patients had more than one autoimmune disease; ‡HT in 20.7% (248/1,199) of patients, Graves' disease in 1.2% (15/1,199) of patients, and 
diagnosis of autoimmune thyroid disease is not specified in 3.5% (42/1,199) of patients; §Pernicious anemia in 0.4% (3/751) of patients.
Table 2. The number and combination of autoimmune diseases in CSU patients
AID, No. Prevalence in all CSU 
patients with AID, %*
Prevalence in all CSU 
patients, %†
Number of AID in CSU
One, 304 91.3 25.4
Two, 28 8.4 2.3
Three, 1 0.3 0.1
Four or more, 0 0 0
Combination of CSU with two or more autoimmune diseases
AITD + vitiligo, 12 3.6 1.0
AITD + autoimmune gastritis,‡ 6 1.8 0.5
AITD + rheumatoid arthritis, 3 0.9 0.2
AITD + ankylosing spondylitis, 2 0.6 0.2
AITD + vitiligo + myasthenia gravis, 1 0.3 0.1
AITD + diabetes mellitus type I, 1 0.3 0.1
AITD + celiac disease, 1 0.3 0.1
AITD + antiphospholipid syndrome, 1 0.3 0.1
Vitiligo + alopecia areata, 1 0.3 0.1
Primary biliary cirrhosis + autoimmune gastritis, 1 0.3 0.1
CSU, chronic spontaneous urticaria; AITD, autoimmune thyroid disease; AID, autoimmune diseases.
*Total = 333; †total = 1,199; ‡Two patients had pernicious anemia.
The presence of autoimmune diseases in CSU patients tended to be associated with higher 
disease activity (Table 3, Fig. 1A and B).
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Table 3. Associations between the presence of autoimmune diseases and clinical/laboratory parameters in 
patients with chronic spontaneous urticaria
Parameter AID is present, %  
(No./total)
AID is absent, %  
(No./total)
P value RR (95% CI)
Gender < 0.001 2.31 (1.73–3.08)
F 32.7 (288/881) 67.3 (593/881)
M 14.2 (45/318) 85.8 (273/318)
Presence of angioedema 0.05 1.21 (1.00–1.46)
+ 30.2 (180/596) 69.8 (416/596)
− 24.9 (137/550) 75.1 (413/550)
Family history of AID 0.001 1.99 (1.44–2.75)
+ 63.6 (21/33) 36.4 (12/33)
− 31.9 (72/226) 68.1 (154/226)
Disease activity (UAS7) 0.135 -
Low 22.2 (94/424) 77.8 (330/424)
Moderate 27.1 (88/325) 72.9 (237/325)
High 29.1 (48/165) 70.9 (117/165)
TSH < 0.001* -
↑ 67.6 (23/34) 32.4 (11/34)
Normal 23.7 (143/604) 76.3 (461/604)
↓ 53.6 (15/28) 46.4 (13/28)
Total IgE, kU/L‡ < 0.001 1.9 (1.57–2.30)
< 50 40.1 (151/377) 59.9 (226/377)
≥ 50 21.0 (146/696) 79.0 (550/696)
Basopenia§ < 0.001 2.2 (1.79–2.69)
+ 49.3 (73/148) 50.7 (75/148)
− 22.4 (198/883) 77.6 (685/883)
Eosinopenia§ < 0.001 1.76 (1.35–2.30)
+ 40.6 (41/101) 59.4 (60/101)
− 23.0 (203/884) 77.0 (681/884)
IgG-anti-FcεRIα/IgE 0.429 1.08 (0.88–1.34)
+ 27.5 (25/91) 72,5 (66/91)
− 33.3 (22/66) 66.7 (44/66)
BAT < 0.001 3.32 (2.18–5.06)
+ 67.6 (23/34) 32.4 (11/34)
− 20.3 (25/123) 79.7 (98/123)
BHRA < 0.001 2.9 (1.92–4.37)
+ 70.0 (14/20) 30.0 (6/20)
− 24.1 (34/141) 75.9 (107/141)
ASST < 0.001 1.68 (1.39–2.03)
+ 37.2 (140/376) 62.8 (236/376)
− 22.1 (166/751) 77.9 (585/751)
Type IIb autoimmune CSU 0.02† -
+ 60.0 (9/15) 40.0 (6/15)
+/− 27.8 (35/126) 72.2 (91/126)
− 16.7 (3/18) 83.3 (15/18)
AID, autoimmune disease; RR, risk ratio; CI, confidence interval; F, female; M, male; TSH, thyroid-stimulating 
hormone; +, positive/present; −, negative/absent; ↑, increased; ↓, decreased; BAT, basophil activation test; 
BHRA, basophil histamine release assay; ASST, autologous serum skin test; CSU, chronic spontaneous urticaria.
*Comparison between groups: The number of CSU patients with high normal/high or low TSH levels vs. patients 
with normal TSH levels: P < 0.001; †Comparison between groups: Type IIb autoimmune CSU (+) vs. partly type 
IIb (+/−) CSU: P = 0.01, type IIb autoimmune CSU vs. non type IIb autoimmune CSU (−): P = 0.01, partly type IIb 
autoimmune CSU vs. non type IIb autoimmune CSU: P = 0.402; ‡In previous studies various cut-off values less than 
50 kU/L were used; §Basopenia was defined as blood basophil numbers less than 0.01 × 109/L. For eosinopenia/
low blood eosinophil counts, we used a cutoff of less than 0.05 × 109/L as described before.37
In patients with CSU, the presence of autoimmune diseases, mostly AITD, is 
associated with higher rates of hypothyroidism and hyperthyroidism
The majority (91%) of CSU patients had normal thyroid-stimulating hormone (TSH) levels 
(0.27–3.9 mU/L). Twenty-eight (4%) patients showed low (below 0.27 mU/L) and 34 (5%) 
patients had high normal/high (above 3.9 mU/L) TSH levels.
Of patients with high normal/high TSH levels, 68% (n = 23) had autoimmune diseases; of patients 
with low TSH levels, 54% (n = 15) had autoimmune diseases; of patients with normal TSH levels, 
only 24% (n = 143) had autoimmune diseases (P < 0.001 for all, Table 3). No difference regarding 
autoimmune diseases was seen between patients with low and elevated TSH levels.
Seventy-one percent (27/38) of patients with high normal/high or low TSH levels were 
diagnosed HT or had elevated IgG anti-TPO levels. One patient had Graves' disease and 7 
patients had undefined AITD.
In patients with CSU, comorbid autoimmune diseases are linked to having 
type IIb autoimmune CSU
Patients with any of the definition criteria for aiCSU such as a positive ASST, BAT and/or 
BHRA more often had autoimmune diseases as compared to patients without (Table 3). Risk 
of having autoimmune diseases is 1.7, 2.9 and 3.3 times greater for CSU patients with positive 
ASST, BHRA and BAT as compared to CSU patients with negative results of ASST, BHRA and 
BAT, respectively. CSU patients with detectable IgG anti-FcεRIα/IgE showed similar rates of 
autoimmune diseases as patients without IgG anti-FcεRIα/IgE (Table 3).
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Fig. 1. The presence of autoimmune diseases in CSU patients is associated with higher disease activity (A, B), low 
total IgE levels (C), eosinophil (D) and basophil counts (E). The number of CSU patients: (A) n = 266 (AID+) and n 
= 777 (AID−); (B) total n = 230 (AID+) and total n = 684 (AID−); (C) n = 286 (AID+) and n = 789 (AID−); (D) n = 231 
(AID+) and n = 749 (AID−); (E) n = 258 (AID+) and n = 768 (AID−). 
AID, autoimmune disease; CSU, chronic spontaneous urticaria.
The prevalence of autoimmune diseases was significantly higher in patients who had true 
‘triple-positive’ aiCSU (60%) as compared to patients who were positive only for some but 
not all markers of aiCSU (28%) and patients who had ‘triple-negative’ CSU (17%, Table 3).
Other features of aiCSU, i.e. lower blood eosinophil and basophil counts and lower total IgE 
levels, were also linked to presence of autoimmune diseases in CSU patients (Fig. 1C-E, Table 3).
Markers for autoimmune diseases, in patients with CSU, are associated with 
poor treatment responses to omalizumab
In CSU patients, the prevalence of ANA and/or IgG anti-TPO positivity was significantly 
higher in non-responders to omalizumab treatment (71%, 5/7) as compared to complete 
responders (20%, 4/16, Table 4). ANA and/or IgG anti-TPO were negative in 80% of complete 
responders, 39% of partial responders and 29% of non-responders.
DISCUSSION
The results of our study confirm that around one-third of CSU patients have autoimmune 
comorbidities. Importantly, autoimmune comorbidity is strongly linked to type IIb aiCSU. 
These findings support the concept that aiCSU is a distinct endotype of CSU. They also 
help assess and monitor patients with CSU, especially those with aiCSU, for comorbid 
autoimmune diseases in routine clinical practice.
How common are autoimmune comorbidities in the general population and in patients 
with CSU? Most AID are rare or very rare diseases, whereas others, such as thyroiditis or 
type I diabetes, are more common. A recent population-based study involving ~800,000 
individuals in Catalonia (Spain) investigated the prevalence of 78 autoimmune diseases 
and identified AITD with 5% as the most prevalent one, followed by type I diabetes and 
rheumatoid arthritis (both < 1%).25 In our population of CSU patients (only a few patients 
were also from Catalonia), 25% had comorbid AITD, HT or Graves' disease, indicating that 
AITD is more than 5 times as common in CSU as in the normal population. This is in line 
with the results of numerous previous studies, which reported rates of HT to range from 1% 
to 28% in CSU.17 In our study, vitiligo is also more prevalent in CSU patients as compared to 
the general population (2% vs. < 1%).25 Furthermore, the prevalence of rheumatoid arthritis 
and autoimmune gastritis is likely to be higher in CSU (1% in our study) than in the general 
population (< 1%, Table 1).
In 2% of our patients, CSU was associated with 2 or 3 autoimmune diseases, mostly HT and 
vitiligo, autoimmune gastritis or rheumatoid arthritis, a so-called autoimmune polyglandular 
syndrome. This is in line with previous studies, where vitiligo and rheumatoid arthritis were also 
the most frequently reported autoimmune diseases in combination with AITD and CSU.11, 12,26,27
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Table 4. Response to omalizumab therapy in chronic spontaneous urticaria patients with positive antinuclear 
antibodies and/or IgG anti-TPO
ANA and/or IgG anti-TPO, (No.) Response to omalizumab, % (No.) P value
NR PR CR
+ (20) 71.4 (5) 61.1 (11) 20 (4)
0.012*
− (25) 28.6 (2) 38.9 (7) 80 (16)
TPO, thyroperoxidase; ANA, antinuclear antibodies; NR, non-responders; PR, partial responders; CR, complete 
responders; +, present; −, absent.
*Comparison between groups: NR vs. PR: P = 0.68, NR vs. CR: P = 0.02, PR vs. CR: P = 0.019.
In CSU patients as well as in the general population, autoimmune diseases are associated 
with female sex, older age and having a family history of autoimmune diseases.11,12,22,25,28 In 2 
large retrospective studies, chronic urticaria in female patients was strongly associated with 
AITD, SLE, vitiligo, Henoch-Schönlein purpura,29 rheumatoid arthritis, Sjögren syndrome, 
celiac disease and type I diabetes mellitus.12 Autoimmune diseases that are more prevalent in 
children and young adults, e.g. celiac disease and diabetes mellitus type I,22,28 are also more 
frequently observed in younger CSU patients of our cohort. Caminiti et al.30 previously reported 
that the presence of celiac disease in children with chronic urticaria was significantly more 
frequent than in control children. However, an overall prevalence of autoimmune diseases is 
likely to be lower in young CSU patients than in middle-aged CSU patients.17,31 This might be 
explained by the fact that autoimmunity, including autoimmune CSU, develops with age and 
that most autoimmune diseases appear 10 years after the onset of CSU.12
What are the clinical implications of our findings? AITD presents with euthyroidism or 
hypothyroidism in HT and hyperthyroidism (thyrotoxicosis) in Graves’ disease. HT is linked 
to many other autoimmune diseases, for example, vitiligo.26,32 IgG anti-TPO is considered a 
sensitive marker for both HT and Graves’ disease. IgG anti-TPO appears in 90% of HT patients 
compared to 25%–50% for IgG anti-thyroglobulin.33 In patients with HT, euthyroidism, i.e. 
IgG anti-TPO positivity, normal TSH and thyroid hormone levels, and absence of symptoms, 
or subclinical hypothyroidism can progress to overt hypothyroidism.34 Increased rates of this 
progression are associated with female sex, TSH ≥ 7 mU/L and increased IgG anti-TPO titers.33-36 
The frequency of IgG anti-TPO positivity also increases with age, with a peak at around 50 years.33
Does this mean that adult CSU patients should be screened for IgG anti-TPO? Several 
independent lines of evidence support to do this and suggest that screening CSU patients 
for HT may improve outcomes of both HT and CSU. First, we and others detected an 
increased prevalence of HT diagnosed by serum levels of IgG anti-TPO in >10% of CSU 
patients. It was associated with female sex, older age and higher rates of hypothyroidism.7,12,17 
Hypothyroidism, including subclinical hypothyroidism, is known to be linked to an increased 
risk for cognitive impairment, cardiovascular events and mortality from coronary heart 
disease.34 Levothyroxine treatment may improve the prognosis, decrease the risk of adverse 
cardiovascular events and prevent progression to overt hypothyroidism.34 Secondly, in 
CSU patients, HT was shown to be associated with other organ-specific and/or systemic 
autoimmune diseases including autoimmune polyglandular syndromes.12,33 Therefore, 
diagnosis of HT may help to suspect and reveal other autoimmune comorbidity. Thirdly, HT 
may hint to the presence of aiCSU, which is usually more severe and resistant to omalizumab 
treatment.4,37,38 Furthermore, treatment of hypothyroidism with levothyroxine might be 
associated with improvement of CSU,17,39 although some studies did not confirm this.40
The international urticaria guideline recommends that physicians assess CSU patients for 
thyroid hormones and autoantibodies in the extended diagnostic workup if indicated by 
history.1 In light of the evidence presented above as well as the findings of the present study, 
we recommend that all adult CSU patients7 be screened for IgG anti-TPO. If elevated levels 
are detected, thyroid function should be checked (e.g. TSH, free T4) and tests for aiCSU (e.g. 
ASST, BAT/BHRA) can be performed. If thyroid function is not impaired and symptoms 
are absent, patients should be followed up periodically to monitor for symptoms of 
hypothyroidism and to detect any rise in their TSH and/or development autoimmune diseases 
other than HT (Fig. 2).34,41
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Are comorbid autoimmune diseases in patients with CSU linked to type IIb autoimmunity? 
Our findings show that in CSU, the presence of comorbid autoimmune diseases and a 
positive family history of autoimmune diseases are associated with markers of aiCSU, 
e.g. ‘triple positivity’ and low total IgE, which is in line with previous findings.4,12,42 This 
may be explained by the known co-occurrence of multiple autoimmune phenomena and 
autoimmune diseases. Our observations, on one hand, strengthen the evidence for the 
existence of a distinct autoimmune subtype of CSU. On the other hand, they indicate the 
need to include targeted questions in the history and/or further laboratory diagnostic workup 
of comorbid autoimmune diseases in a subgroup of CSU patients. This is especially true 
for patients who are positive to ASST, BHRA and/or BAT and have autoantibodies detected 
by immunoassay. Surprisingly, we did not see higher rates of autoimmune diseases in 
patients with presence of IgG anti-FcεRIα/IgE. This might be explained by the fact that these 
antibodies are nonfunctional in some patients and were also described in healthy people.43
Patients with aiCSU are likely to have a worse and slow response to omalizumab38,44 and a 
good response to cyclosporine45 and inhibition of Bruton's tyrosine kinase by fenebrutinib 
(Metz et al., personal communication). Whether the presence of comorbid autoimmune 
diseases can also predict response to treatment in CSU patients is unknown. We found that 
the presence of ANA and/or IgG anti-TPO, markers for autoimmunity and autoimmune 
diseases, was associated with non-response to omalizumab treatment. This is in line with 
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TSH ↑, free T4 ↓
TSH ↑, free T4 N
Symptoms are absent
IgG-anti-TPO, free T4, TSH Adult patients: IgG-anti-TPO
• Consider another diagnosis
• Consider referral*
• Consider LT treatment
• Consider referral*
• Consider reassessment
in 1–3 years if CSU persists
• Free T4, TSH
• Consider testing for aiCSU
• Repeat measurement
• Consider LT treatment
• Consider referral*
• Consider repeat
measurement in 2–4 weeks
• Consider referral*
• Repeat free T4 measurement
• If TSH > 7.0 mU/L: consider
referral* and LT treatment to
reduce risk of CHD events
Ask all CSU patients for signs and symptoms of Hashimoto's thyroiditis
Confirmation of euthyroidism, subclinical or overt hypothyroidism
For example, fatigue, loss of energy, decreased appetite, cold intolerance, dry skin,
hair loss, inability to concentrate, constipation, blurred vision and other
1
2
Fig. 2. General approach to the management of Hashimoto's thyroiditis and hypothyroidism in patients with CSU 
(modified from 34). 
CSU, chronic spontaneous urticaria; TPO, thyroperoxidase; TSH, thyroid-stimulating hormone; LT, levothyroxine; 
aiCSU, autoimmune chronic spontaneous urticaria; CHD, coronary heart disease. 
*Referral to an endocrinologist.
recently reported data from a cohort of Turkish CSU patients, where poor response to 
omalizumab treatment was also linked to ANA-positivity.46 In addition, in small studies and 
reports, omalizumab was less effective in patients with CSU and IgG anti-TPO.47,48 In other 
studies, cyclosporine was more effective in CSU patients with ASST and/or BHRA positivity 
and raised thyroid autoantibodies.49,50
The major strength of the current study is the inclusion of a large cohort of patients from 12 
European centers and assessment of many parameters, including triple testing for aiCSU. The 
retrospective analysis is a limitation of our study. The data from the patients was extracted from 
different centers in different countries and it can be expected that the diagnosis, management 
and treatment of patients differ significantly among centers and countries. Moreover, we 
compared aiCSU patients with patients with non type IIb autoimmune CSU rather than those 
with type I autoimmune CSU. This is a limitation of this study and needs to be addressed by 
future studies. Importantly, such studies need to also compare patients with type I and type 
IIb autoimmune CSU with patients who have both type I and type IIb autoimmune CSU, a 
subpopulation of CSU patients that is currently ill characterized in terms of its rate and clinical 
characteristics.51 In addition, the 3 markers for aiCSU, i.e. basophils tests, ASST and IgG anti-
FcεRIα/IgE, were only analyzed, in combination, in the patients from the PURIST study. The 
therapeutic response to omalizumab was evaluated only in a small subgroup of patients. Finally, 
some of the routine analyses were not performed by a central laboratory, rather than the centers 
involved, which may have increased the heterogeneity of data.
In conclusion, autoimmune diseases, especially HT and vitiligo, are common in CSU 
and linked to aiCSU and poor response to treatment with omalizumab. In CSU patients, 
autoimmune diseases are often overlooked, usually occur as CSU persists, can be treated and 
prevented by early treatment, and treatment can have positive effects on CSU. Therefore, 
we recommend that CSU patients be assessed for features of aiCSU and be investigated, at 
the onset of their urticaria and at regular intervals, for comorbid autoimmune diseases. In 
all adult CSU patients, we strongly recommend a) checking for symptoms of autoimmune 
diseases and screening for IgG anti-TPO with annual reassessment of thyroid function in 
positive asymptomatic cases; and b) a follow-up on a regular basis of patients with aiCSU, 
especially female patients with HT and/or a positive family history, to screen for signs and 
symptoms of other autoimmune diseases.11,41 Further studies are needed and should use 
additional markers for aiCSU, for example total IgE52 or the ratio of IgG anti-TPO to total IgE, 
a recently reported marker for aiCSU.4
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